summary
The newly issued patent combining interstitial and brachytherapy treatment comes as Novian Health is conducting multi-center studies of its Novilase Interstitial Laser Therapy (ILT) System for the treatment of small tumor breast cancer. The company is currently enrolling patients in the United States, United Kingdom and France. Continue reading
prREACH
Dec 09, 2013 /prREACH/ --
CHICAGO--Novian Health, developer of Novilase® Breast Therapy, announced the company has received a Notice of Allowance for a new patent. The U.S. patent, Application No. 12/778,580, covers interstitial laser therapy in combination with interstitial brachytherapy treatment. The technology could make breast cancer treatment more efficient and also reduce treatment time.
The newly issued patent comes as Novian Health is conducting multi-center studies of its Novilase Interstitial Laser Therapy (ILT) System for the treatment of breast cancer. The company is currently enrolling patients in the U.S., United Kingdom and France.
“The new patent covers technology that has the potential to simplify and improve therapy for breast cancer patients,” said Henry “Chip” Appelbaum, President and CEO of Novian Health. “This achievement further validates Novilase technology -- and buttresses our already strong portfolio of intellectual property covering the monitoring and control of tumor ablation.”
Novian developed the Novilase ILT System for the ablation of small (up to 20 mm) malignant breast tumors. The company has previously received FDA 510(k) clearance for the treatment of breast fibroadenomas and currently offers Novilase at breast centers around the country that are participating in its ABLATE registry and in the Breast Cancer trial (BR-002).
About Novilase Novilase is a laser-based device for destroying tumors. This minimally invasive alternative to conventional surgery provides a safe tumor treatment alternative while preserving the patient’s options for additional procedures or adjunctive therapies. This image-guided outpatient procedure does not require general anesthetic or a hospital stay. Multiple tumors can be treated during a single visit. Therapy outcomes may be assessed using a variety of currently available imaging technologies and other methods. Therapy consists of physician placement of two small gauge needles into the tumor site after local anesthetic, followed by initiation of the computer-controlled Novilase system. Treatment times vary from 15-30 minutes.
About Novian Health Novian Health Inc., located in Chicago, is a privately held medical device company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy (ILT). Developed as an alternative to surgery, the company’s technology uses parametrically controlled heating for the ablation of tumors. Image-guided treatment of breast tumors is the first application of the technology, and Novilase also has the potential to treat tumors elsewhere in the body.
For more information, call (312) 266-7200 or access www.novianhealth.com and www.novilase.com.
Contact: Liz Dowling Dowling & Dennis Public Relations E-mail: [email protected]